Canada Life
ITOS

Canada Life’s iTeos Therapeutics ITOS Stock Holding History

Canada Life’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-785
Closed -$8K – 2048
2024
Q3 		$8K Hold
785
– – ﹤0.01% 2067
2024
Q2 		$12K Hold
785
– – ﹤0.01% 2080
2024
Q1 		$11K Hold
785
– – ﹤0.01% 2128
2023
Q4 		$9K Sell
785
-20,610
-96% -$204K ﹤0.01% 2155
2023
Q3 		$235K Hold
21,395
– – ﹤0.01% 1831
2023
Q2 		$282K Sell
21,395
-2,071
-9% -$29.5K ﹤0.01% 1796
2023
Q1 		$319K Sell
23,466
-1,812
-7% -$32.5K ﹤0.01% 1795
2022
Q4 		$493K Buy
25,278
+568
+2% +$11.1K ﹤0.01% 1726
2022
Q3 		$470K Buy
24,710
+4,418
+22% +$102K ﹤0.01% 1693
2022
Q2 		$418K Buy
20,292
+3,280
+19% +$77.8K ﹤0.01% 1711
2022
Q1 		$560K Buy
17,012
+16,227
+2,067% +$590K ﹤0.01% 1683
2021
Q4 		$36K Buy
+785
New +$26.1K ﹤0.01% 2263
2021
Q2 		– Sell
-929
Closed -$31K – 2574
2021
Q1 		$31K Hold
929
– – ﹤0.01% 2436
2020
Q4 		$31K Buy
+929
New +$24.6K ﹤0.01% 2444

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Canada Life's ITOS Position: Q4 2024 in Review

Canada Life sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 785 shares — an estimated $8K sold.

Canada Life first reported a position in ITOS in Q4 2020 and held it in 14 quarters. The position peaked at $560K in Q1 2022. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Canada Life reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Canada Life sold 785 iTeos Therapeutics shares in Q4 2024, an estimated $8K.
  • Canada Life first reported a position in iTeos Therapeutics in Q4 2020 and held it in 14 quarters.
  • Canada Life's iTeos Therapeutics position peaked at $560K in Q1 2022.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Canada Life's 13F filing for Q4 2024, filed 13 Feb 2025.